Making Alzheimer's
Just a Memory

SCROLL

Alzamend Neuro, Inc.

Committed to Prevention, Treatment and Cure of Alzheimer’s Disease

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

×

We are driven by the belief that strong support of research is the foundation for true innovation.

Publications

Recently Published Articles

Statistics

13 million
The number of Americans projected currently living with Alzheimer’s disease in 2021
6.2 million
The number of Americans that provide unpaid care for people with Alzheimer’s or other Dementias
11 million
The number of Americans that provide unpaid care for people with Alzheimer’s or other Dementias
Previous
Next